Cost-effectiveness of Alzheimer's disease CSF biomarkers and amyloid-PET in early-onset cognitive impairment diagnosis

This study aimed at determining the cost-effectiveness of amyloid-positron emission tomography (PET) compared to Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarkers (amyloid-?42, total-Tau and phosphorylated-Tau) for the diagnosis of AD in patients with early-onset cognitive impairmen...

Descripción completa

Detalles Bibliográficos
Autores: Contador Muñana, José Miguel, Vargas Martinez, A. M., Sánchez Valle, Raquel, Trapero Bertran, M., Lladó Plarrumaní, Albert
Tipo de recurso: artículo
Estado:Versión aceptada para publicación
Fecha de publicación:2022
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/206227
Acceso en línea:https://hdl.handle.net/2445/206227
Access Level:acceso abierto
Palabra clave:Malaltia d'Alzheimer
Tomografia per emissió de positrons
Alzheimer's disease
Positron emission tomography
id ES_12ae0bc01ce968d148f8fa862806cd29
oai_identifier_str oai:recercat.cat:2445/206227
network_acronym_str ES
network_name_str España
repository_id_str
spelling Cost-effectiveness of Alzheimer's disease CSF biomarkers and amyloid-PET in early-onset cognitive impairment diagnosisContador Muñana, José MiguelVargas Martinez, A. M.Sánchez Valle, RaquelTrapero Bertran, M.Lladó Plarrumaní, AlbertMalaltia d'AlzheimerTomografia per emissió de positronsAlzheimer's diseasePositron emission tomographyThis study aimed at determining the cost-effectiveness of amyloid-positron emission tomography (PET) compared to Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarkers (amyloid-?42, total-Tau and phosphorylated-Tau) for the diagnosis of AD in patients with early-onset cognitive impairment. A decision tree model using a national health care perspective was developed to compare the costs and effectiveness associated with Amyloid-PET and AD CSF biomarkers. Available evidence from the literature and primary data from Hospital Clínic de Barcelona were used to inform the model and calculate the efficiency of these diagnostic alternatives. Medical visits and diagnostic procedures were considered and reported in €2020. We calculated the incremental cost-effectiveness ratio to measure the cost per % of correct diagnoses detected and we perform one-way deterministic and probabilistic sensitivity analyses to assess the uncertainty of these results. Compared with AD CSF biomarkers, Amyloid-PET resulted in 7.40% more correctly diagnosed cases of AD, with an incremental total mean cost of €146,854.80 per 100 cases. We found a 50% of probability that Amyloid-PET was cost-effective for a willingness to pay (WTP) of €19,840.39 per correct case detected. Using a WTP of €75,000, the probability that it is cost-effective reached a maximum of 76.9%, thus leading to a conclusion that Amyloid-PET is not a cost-effective technique compared to AD CSF biomarkers, unless the funder is willing to pay a minimum of €19,840.39 to detect one more correct case. Furthermore, obtaining CSF provides simultaneous information on amyloid ? and tau biomarkers and allows other biomarkers to be analyzed at a relatively low cost.© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.Springer2024202420222024info:eu-repo/semantics/articleinfo:eu-repo/semantics/acceptedVersion33 p.application/pdfhttps://hdl.handle.net/2445/206227Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésVersió postprint del document publicat a: https://doi.org/10.1007/s00406-022-01439-zEuropean Archives Of Psychiatry And Clinical Neuroscience, 2022, vol. 273, num. 1, p. 243-252https://doi.org/10.1007/s00406-022-01439-z(c) Springer, 2022info:eu-repo/semantics/openAccessoai:recercat.cat:2445/2062272026-05-29T05:05:01Z
dc.title.none.fl_str_mv Cost-effectiveness of Alzheimer's disease CSF biomarkers and amyloid-PET in early-onset cognitive impairment diagnosis
title Cost-effectiveness of Alzheimer's disease CSF biomarkers and amyloid-PET in early-onset cognitive impairment diagnosis
spellingShingle Cost-effectiveness of Alzheimer's disease CSF biomarkers and amyloid-PET in early-onset cognitive impairment diagnosis
Contador Muñana, José Miguel
Malaltia d'Alzheimer
Tomografia per emissió de positrons
Alzheimer's disease
Positron emission tomography
title_short Cost-effectiveness of Alzheimer's disease CSF biomarkers and amyloid-PET in early-onset cognitive impairment diagnosis
title_full Cost-effectiveness of Alzheimer's disease CSF biomarkers and amyloid-PET in early-onset cognitive impairment diagnosis
title_fullStr Cost-effectiveness of Alzheimer's disease CSF biomarkers and amyloid-PET in early-onset cognitive impairment diagnosis
title_full_unstemmed Cost-effectiveness of Alzheimer's disease CSF biomarkers and amyloid-PET in early-onset cognitive impairment diagnosis
title_sort Cost-effectiveness of Alzheimer's disease CSF biomarkers and amyloid-PET in early-onset cognitive impairment diagnosis
dc.creator.none.fl_str_mv Contador Muñana, José Miguel
Vargas Martinez, A. M.
Sánchez Valle, Raquel
Trapero Bertran, M.
Lladó Plarrumaní, Albert
author Contador Muñana, José Miguel
author_facet Contador Muñana, José Miguel
Vargas Martinez, A. M.
Sánchez Valle, Raquel
Trapero Bertran, M.
Lladó Plarrumaní, Albert
author_role author
author2 Vargas Martinez, A. M.
Sánchez Valle, Raquel
Trapero Bertran, M.
Lladó Plarrumaní, Albert
author2_role author
author
author
author
dc.subject.none.fl_str_mv Malaltia d'Alzheimer
Tomografia per emissió de positrons
Alzheimer's disease
Positron emission tomography
topic Malaltia d'Alzheimer
Tomografia per emissió de positrons
Alzheimer's disease
Positron emission tomography
description This study aimed at determining the cost-effectiveness of amyloid-positron emission tomography (PET) compared to Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarkers (amyloid-?42, total-Tau and phosphorylated-Tau) for the diagnosis of AD in patients with early-onset cognitive impairment. A decision tree model using a national health care perspective was developed to compare the costs and effectiveness associated with Amyloid-PET and AD CSF biomarkers. Available evidence from the literature and primary data from Hospital Clínic de Barcelona were used to inform the model and calculate the efficiency of these diagnostic alternatives. Medical visits and diagnostic procedures were considered and reported in €2020. We calculated the incremental cost-effectiveness ratio to measure the cost per % of correct diagnoses detected and we perform one-way deterministic and probabilistic sensitivity analyses to assess the uncertainty of these results. Compared with AD CSF biomarkers, Amyloid-PET resulted in 7.40% more correctly diagnosed cases of AD, with an incremental total mean cost of €146,854.80 per 100 cases. We found a 50% of probability that Amyloid-PET was cost-effective for a willingness to pay (WTP) of €19,840.39 per correct case detected. Using a WTP of €75,000, the probability that it is cost-effective reached a maximum of 76.9%, thus leading to a conclusion that Amyloid-PET is not a cost-effective technique compared to AD CSF biomarkers, unless the funder is willing to pay a minimum of €19,840.39 to detect one more correct case. Furthermore, obtaining CSF provides simultaneous information on amyloid ? and tau biomarkers and allows other biomarkers to be analyzed at a relatively low cost.© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
publishDate 2022
dc.date.none.fl_str_mv 2022
2024
2024
2024
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/acceptedVersion
format article
status_str acceptedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/206227
url https://hdl.handle.net/2445/206227
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Versió postprint del document publicat a: https://doi.org/10.1007/s00406-022-01439-z
European Archives Of Psychiatry And Clinical Neuroscience, 2022, vol. 273, num. 1, p. 243-252
https://doi.org/10.1007/s00406-022-01439-z
dc.rights.none.fl_str_mv (c) Springer, 2022
info:eu-repo/semantics/openAccess
rights_invalid_str_mv (c) Springer, 2022
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 33 p.
application/pdf
dc.publisher.none.fl_str_mv Springer
publisher.none.fl_str_mv Springer
dc.source.none.fl_str_mv Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869403631597387776
score 15,811543

Similares en LA Referencia